With all the buzz in gene therapy, Sanofi offloads two small molecule sickle cell programs from $11.6B buyout to Global Blood Therapeutics

Standing by a small molecule approach in sickle cell disease even as gene therapy and gene editing players tout landmark breakthroughs, Global Blood Therapeutics has turned to Sanofi to beef up its pipeline.